Therapeutic drug monitoring of TNFinhibitors and other therapeutic antibodies.
Develop assays for novel immunotherapy drugs such as pembrolizumab, nivolumab and ipilimumab for monitoring drug levels in patients with lung cancer and malignant melanoma.
Develop assays for measuring rituximab and anti-rituximab for monitoring drug level and anti-drug antibody formation.
Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
Recent publications
Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK(2022) Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study Lancet Rheumatol(in press) DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604
Huynh TTM, Aass HCD, Falk RS, Astrup GL, Helland Å, Bjøro T, Bjordal K, Dale E, Hellebust TP, Herlofson BB, Malinen E, Kiserud CE, Osnes T, Amdal CD(2022) Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy J Cancer Surviv, 1-12(in press) DOI 10.1007/s11764-022-01273-1, PubMed 36350483
Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL(2022) Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy RMD Open, 8(2) DOI 10.1136/rmdopen-2022-002417, PubMed 36328399